Compared with the survivor group, the nonsurvivor group had a lower BMI level, a lower proportion of patients using ACEI/ARB drugs (P < 0.05), and higher proportions of patients with baseline Alb < 30 g/L, anemia and AKI (P < 0.05). This evidence concerns the gene ALB and anemia.